
Author Index Volumes 1–2

The volume numbers are printed in italics

Angibaud P, see End DW (2007) *1*: 115–150

Arts J, see ten Holte P (2007) *1*: 273–311

Berg S, see Bhat RV (2007) *2*: 137–174

Bhat RV, Berg S, Burrows J, Lindquist J (2007) GSK-3 Inhibitors for the Treatment of Alzheimer's Disease. *2*: 137–174

Blake JE, see Wallace EM (2007) *1*: 65–114

de Bono JS, see ten Holte P (2007) *1*: 273–311

Boschelli DH (2007) Bcr-Abl Kinase Inhibitors. *1*: 387–424

Bradbury RH (2007) Overview. *1*: 1–17

Brodney MA, see Lau L-F (2007) *2*: 1–24

Burrows J, see Bhat RV (2007) *2*: 137–174

Bush AI, see White AR (2007) *2*: 107–136

Van Emelen K, see ten Holte P (2007) *1*: 273–311

End DW, Mevellec L, Angibaud P (2007) Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress in the Clinic. *1*: 115–150

Fong PC, see ten Holte P (2007) *1*: 273–311

Galemmo Jr RA, see Moriarty KJ (2007) *1*: 189–271

Garcia-Echeverria C (2007) Survival Signaling. *1*: 151–188

Grossberg G, see Kao J (2007) *2*: 25–51

Hoffmann J, Sommer A (2007) Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer. *1*: 1–64

ten Holte P, Van Emelen K, Janicot M, Fong PC, de Bono JS, Arts J (2007) HDAC Inhibition in Cancer Therapy: an Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit. *1*: 273–311

Janicot M, see ten Holte P (2007) *1*: 273–311

Jiang Q, Mandrekar S, Landreth G (2007) PPAR γ Agonists for the Treatment of Alzheimer's Disease. *2*: 81–106

Johnson DL, see Moriarty KJ (2007) *1*: 189–271

Kao J, Grossberg G (2007) Cholinesterase Inhibitors. *2*: 25–51

Koblish H, see Moriarty KJ (2007) *1*: 189–271

- Laird ER, see Wallace EM (2007) *1*: 65–114
- Landreth G, see Jiang Q (2007) *2*: 81–106
- Lau L-F, Brodney MA (2007) Therapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview. *2*: 1–24
- Lindquist J, see Bhat RV (2007) *2*: 137–174
- Lyssikatos J, see Wallace EM (2007) *1*: 65–114
- Mandrekar S, see Jiang Q (2007) *2*: 81–106
- Mevellec L, see End DW (2007) *1*: 115–150
- Moriarty KJ, Koblisch H, Johnson DL, Galemno Jr RA (2007) Progress in the Development of Agents to Control the Cell Cycle. *1*: 189–271
- Paz K, Zhu Z (2007) Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy. *1*: 313–362
- Sawyer TK (2007) Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy. *1*: 363–385
- Soares HD, Sparks DL (2007) Beyond Cholesterol: Statin Benefits in Alzheimer's Disease. *2*: 53–80
- Sommer A, see Hoffmann J (2007) *1*: 1–64
- Sparks DL, see Soares HD (2007) *2*: 53–80
- Wallace EM, Yeh TC, Laird ER, Blake JF, Lyssikatos J (2007) Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. *1*: 65–114
- White AR, Bush AI (2007) Metal Complexing Agents for the Treatment of Alzheimer's Disease. *2*: 107–136
- Yeh TC, see Wallace EM (2007) *1*: 65–114
- Zhu Z, see Paz K (2007) *1*: 313–362

Subject Index

- Acetylcholine 28
- Acetylcholinesterase 28
 - inhibitors 25, 28
- Aging, metals 109
- Alsterpaullone 152
- Alzheimer's disease cholesterol lowering trial (ADCLT) 67
- Amapkines 11
- Aminopyrazinyl-2-carboxamides 146, 159
- Amyloid 1, 81, 107
 - cascade hypothesis 4
- Amyloid pathologies 3, 86
 - targeting 11
- Amyloid precursor protein (APP) 142
- Amyloid, in vitro dissolution 124
- Amyloidosis 142
- Angiotensin converting enzyme 13
- Anilino-arylmaleimides 146, 162
- ApoE 81
- Apolipoproteins 68, 69
- APP 53, 109, 142
 - modulation, Cu homeostasis 118
- APP-Cu mediated neurotoxicity 117
- APPN-terminal Cu-binding domain 116
- APPN-terminal Zn-binding domain 121
- AR-A014418 156
 - in vivo efficacy 158
 - pharmacokinetic properties 158
- Atorvastatin 60, 69
 - treatment, plasma biomarkers 67
- AZ10316813 161
- AZ11125357 159
- A β 3, 60, 62
 - Fe 122
 - vaccine 14
 - Zn interactions 120
- A β peptide 3
 - pathological Cu interactions 113
- BACE 109
 - , inhibitors 12
- Beta amyloid 137
- Bisarylmaleimides 146, 162
- Butyrylcholinesterase 28
- Caloric restriction 8
- Cardiovascular risk factors 6
- Casein kinase-1 (CK-1) 14
- CDK1/cyclin B 150
- Chelators, hydrophilic 128
- Cholesterol 6, 53, 56, 59, 64
- Cholesterol-lowering agent to slow progression (CLASP) study 60
- Choline acetyltransferase 28
- Cholinesterase 28
- Cholinesterase inhibitors 28, 33
 - brain anatomical changes 43
 - memantine 44
- Clioquinol 107
- Cognition 59
- Combination treatment 44
- Copper 107, 111
 - homeostasis 111
- CQ 127
- Cyclin-dependent kinase 5 (Cdk5) 14
- Cyclohexanehexol 14
- Cytokines 6
- Dementia pugilistica 7
- Dementia-related illnesses, cholinesterase inhibitors 45
- Diabetes, type 2 7
- Diagnostic criteria 27
- Donepezil 9, 25, 30, 35
- Dyslipidemia 88
- Endothelin converting enzymes (ECE) 13
- Energy disorders 6

- Energy metabolism 93
Environmental risk factors 6
Epidemiological studies, cholesterol 56
– statin 56
Etiology 6
Extracellular signal-regulated kinases (ERK) 14
- Fe 122
– APP 123
– homeostasis 122
- GAB2 5
Galantamine 11, 25, 32, 40
Gamma secretase 109
Geriatric depression scale (GDS) 60
Glycogen synthase (GS) 139
Glycogen synthase kinase 137, 143
GSK-3 138
– activity, regulation 139
– amyloidosis 142
– brain, expression 138, 140
– inhibitors 138, 145, 156, 159, 168
– neuronal death 142
- Herperzine 11
Hippocampus 3
24S-Hydroxycholesterol (cerebrosterol) 53, 67
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors 56
Hymenialdisine 146, 149
Hypercholesterolemia 6, 61
Hyperhomocysteinaemia 7
Hypertension 7
- Indirubins 146, 154
Inflammation 92
Insulin degrading enzyme (IDE) 7, 13
Insulin sensitivity 95
Interleukins 69
- Kinase inhibition 150, 152, 161, 167
- Lipid lowering agents (LLA) 59
Lipid rafts 7
Lipitor enhancement of aricept (LEADe) 60
Lipoprotein receptor-related protein (LRP) 13
- Lithium, long-term potentiation 149
– tau/beta amyloid 148
Lithium chloride 146, 147
Long-term potentiation 4, 66, 141
Lovastatin 57, 60
Low density lipoprotein receptor 53
LXR 81
- Maleimides 163
Memantine 44
Metabolic disorders 6
Metal ligands, inhibitors of A β aggregation and neurotoxicity 124
Metals, aging 109
N-Methyl-D-aspartate (NMDA) receptor antagonist 9, 11
Microgliosis 1, 5
– targeting 15
Microtubule-affinity regulating kinase (MARK) 14
Mild cognitive impairment (MCI) 3
Mini mental state exam (MMSE) 35, 59
Morris water maze 8
MPAC 107
- National Institute of Clinical Excellence, recommendations 47
Neurodegeneration 1, 3
Neurofibrillary tangles 3, 88, 138
Neuroinflammation 1
Neuronal death 3, 142
Nicotinic agonists 11
Nitrothiazole urea 146, 156
NMDA receptor antagonist 9, 11
Non-steroidal antiinflammatory drugs (NSAIDs) 15
- Oxidative stress 112
Oxindolequinazolines 146, 161
- P-glycoprotein 13
p38 14
Pathogenesis 26
Pathology 3, 86
Pathophysiology 88
Paullones 146, 152
PBT-2 14
Pentraxins 72
Plasma biomarkers 67
Plasmin 13

- PPAR γ 15, 81, 83, 86
– agonist therapy 97
– agonists, animal models 97
– transcriptional regulation 84
Pravastatin 57, 60
Presenilin 55
Protein kinase 145
“Punch drunk” syndrome 7
- R-flurbiprofen 12
RAGE inhibitors 13
Rivastigmine 11, 25, 31, 37
Rosuvastatin 60
- SB-216763 163
SB-415286 163
 γ -Secretase inhibitors 11
Serum amyloid P 53
Serum glutamic-oxaloacetic transaminase (SGOT) 29
Serum glutamic-pyruvic transaminase (SGPT) 29
Simvastatin 57, 60
Statins 53, 59
Symptoms, targeting 9
- Tacrine 9, 25, 29
Tau (microtubule-associated protein) 1, 137, 140
– amyloid 140
– metal interactions 123
– paired helical filaments (PHFs) 141
– straight filaments (SFs) 141
– pathologies/targeting 4, 14
– splicing 158
Tau kinase inhibitors 14
TDZD-8 166
Therapeutic strategies 8
Thiadiazolidinones 146, 166
Tramiprosate 14
Transactivation mechanism 85
Transrepression mechanisms 85
Traumatic brain injury 6
Type 2 diabetes 7
Tyrosine kinase ZAK1 139
- Zinc 119
–, homeostasis 119
–, metalloproteases 121
–, metalloproteins 121